Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV – Sofia ref.: 115842 (VSV-EBOVAC)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative 2
Action type: Research and Innovation actions
Partnership: IMI2 (Art-187)
Countries involved: Germany,Italy,Switzerland,Sweden,Switzerland,Netherlands,United States,United Kingdom,United Kingdom,Gabon
Call: Vaccine development Phase I, II, and III (H2020-JTI-IMI2-2014-02-single-stage, 2014)
Start date: 2015-03-01
End date: 2019-02-28
Duration (months): 48.0
Total project cost (EUR): 4786010.0
EU funding (EUR): 3887260.0
Participants: 13
Project status: CLOSED

The proposal, VSV-EBOVAC, directly addresses the topic 1 of the IMI2 call on Ebola by supporting the clinical development of a highly promising new Ebola vaccine candidate, the vesicular stomatitis virus (VSV)‐ vectored Zaire Ebola vaccine (VSV-ZEBOV). In non-human primates, a single dose of VSV-ZEBOV elicited a strong (100%) and long-lasting protective efficacy against Ebola Zaire infections. Developed by Public Health Canada and manufactured by NewLink Genetics, VSV-ZEBOV was thus selected by the World Health Organization (WHO) as one of the 2 most promising vaccine candidates. To accelerate its clinical development, the WHO has organized a consortium and supported the organization of parallel first-in-man Phase I/II clinical trials, both in Europe and Africa. The primary objectives of these trials, initiated mid-November 2014, are to study the safety and antibody-inducing capacity of various doses of VSV-ZEBOV in European and African populations. We propose to build upon this asset to acquire new and critical knowledge of the innate and adaptive immune responses elicited in humans by VSV-ZEBOV vaccination, with specific emphasis on trancriptomics and metabolomics signatures. To this aim, we have constructed a consortium including representatives from the vaccine manufacturer, scientists of the 3 main clinical sites (Switzerland, Gabon, Kenya) and world-leaders in immunology and partners of ADITEC, a large FP7- supported collaborative research programme aiming to accelerate the development of novel, powerful immunisation technologies for next-generation vaccines. We propose an ambitious program using cutting-edge technologies to perform an in depth characterization of the clinical samples harvested before/after VSV-ZEBOV immunization of 200 volunteers in Switzerland, Gabon and Kenya, and to extend the recently initiated clinical studies up to 12 months to identify the signatures and determinants of persistent immune responses.

Keywords: vaccine safety immunogenicity signatures ebola
Global Lensing Observations to go Beyond Einstein (GLOBE)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Universe sciences
Panel description: Astro-physics/-chemistry/-biology; solar system; planetary systems; stellar, galactic and extragalactic astronomy; cosmology; space sciences; astronomical instrumentation and data
Countries involved: United Kingdom
Call: ERC Consolidator Grant (ERC-2014-CoG, 2014)
Start date: 2015-11-01
End date: 2021-10-31
Duration (months): 72.0
Total project cost (EUR): 1995797.0
EU funding (EUR): 1995797.0
Participants: 1
Project status: CLOSED

This ERC Consolidator grant will push forward the boundaries in our understanding of gravity by confronting the most advanced theoretical framework for modified gravity models with this decade’s ultimate set of observations. Using three state-of-the-art, same-sky lensing spectroscopy surveys, which are the only deep surveys currently in existence to have this unique complementarity, we will undertake a ground-breaking gravity experiment on some of the largest scales observed in the Universe. Our findings could show that we need to go beyond Einstein to bring about a revolution in our understanding of gravity on cosmological scales, transforming our understanding of the dark universe. My analysis will combine two gravity probes; the non-relativistic motion of galaxies detected through redshift-space distortions, and the relativistic motion of light detected through the weak gravitational lensing of distant galaxies. The same-sky combination of these probes provides the best long-term prospect for observing if matter bends space differently to time, and if the gravitational constant G evolves. As the main objective of this research could be so far reaching, it is imperative that it is approached with care, using a meticulous analysis. Using novel techniques that exploit the same-sky nature of these surveys, we will improve the accuracy and precision of our results, understanding and removing sources of systematic errors inherent in both gravity probes. This will enable my ERC team to carry out pioneering dark universe science, confident that our results are truly probing fundamental physics rather than residual systematic subtleties of the data.

Keywords: observational and theoretical cosmology,gravitational lensing and galaxy redshift surveys,modified gravity
Nanoscale Thermo Optical Sensing (NaTOS)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Physics
Countries involved: Netherlands
Call: Individual Fellowships (H2020-MSCA-IF-2017, 2017)
Start date: 2018-03-01
End date: 2020-02-29
Duration (months): 24.0
Total project cost (EUR): 165598.8
EU funding (EUR): 165598.8
Participants: 1
Project status: CLOSED

NaTOS: Nanoscale Thermo Optical Sensing is the concept of a new truly label free bio-sensor device capable of monitoring transient molecular interactions. The sensor utilizes plasmonic gold nanorods (NR) as both nanoscale heating source and optical near field sensor. Proteins and enzymes will be monitored as they change the intensity scattered by a single NR as they diffuse through the nanorod's nearfield. The simultaneous laser induced and thus tunable heating of the NR will induces a nanoscale temperature gradient that allows to probe the analytes with respect to their thermophoretic behavior. This analyte specific behavior provides specific thermophortic fingerprints which will be used to identify and distinguish between different proteins and in further extend also to monitor the interaction between different species of analytes. This novel type of sensor does not require fluorescent labels nor does it rely on tethering of specific receptors and the consequent binding of analytes to the NRs. In contrast to current state of the art techniques this truly label-free sensor does not suffer from binding induced life time restrictions and can obtain statistical significant datasets without the requirement, but with the possibility of multiplexing.

Keywords: biosensor,label free,plasmonic nanoparticles,thermophoresis
Enhancing and Strengthening the Excellence in Interdisciplinary Biomedical Research at TRANSCEND (ESEI-BioMed)

Framework: Horizon 2020 — Spreading excellence and widening participation
Programme: ERA chairs
Theme: Attracting and mobilising the best talents
Action type: Coordination and support actions
Countries involved: Romania
Call: ERA Chairs (H2020-WIDESPREAD-2018-2020-6, 2019)
Start date: 2021-01-01
End date: 2026-12-31
Duration (months): 72.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

TRANSCEND, designed as a translational research centre at the Regional Institute of Oncology (IRO), an university hospital, due to the EU Structural Funds, is in a emergent stage of its development. The centre, planned to generate a translational repertoire of biomarkers capable to develop the diagnostic tumor taxonomy and to keep going the personalized therapy, was founded on the interdisciplinary interplay between several cell and molecular high-throughput technologies. It therefore offers a stimulating and dynamic scientific and clinical environment to reach its maximum potential by extending the current scientific aims to a more pronounced inter-, multi- and transdisciplinary approach of the biomedical research. Such a goal will be fulfilled by exploring the huge opportunities brought by nanomedicine in development of less expensive and more powerful devices and functionalized nanocarriers used for the diagnosis and treatment of human diseases. Hence, the ambitious goal of the ESEI-BioMed project is to enhance and strengthen the excellence of the interdisciplinary biomedical research at the TRANSCEND research centre. To meet this objective, a highly successful and experienced leadership (ERA Chair holder) whose experience and professional value, including a range of skills from excellent research manager to excellent researcher in the field of nanomedicine-oriented research, will be hired aiming at implementing positive changes in the actual organization of the centre. The interdisciplinary scientific plan and the management skills of the ERA-Chair holder will certainly be the catalysts of the creation of an interdisciplinary team made of highly-skilled and dedicated researchers capable to properly address the scientific challenges and finally to increase the international visibility, translational capability and socio-economic impact of the TRANSCEND.

Keywords: nanomedicine,nano bio materials,nano bio sensors,nanodrugs,therapy,diagnostic
Competitive Auxiliary Power Units for vehicles based on metal supported stack technology (COMPASS)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Theme: Public-private partnerships
Destination: Fuel Cells and Hydrogen
Action type: Research and Innovation actions
Partnership: FCH2 (Art-187)
Countries involved: Austria,Germany,Austria,United Kingdom
Call: Develop technologies for achieving competitive solutions for APU transport applications based on existing technology (H2020-JTI-FCH-2015-1, 2015)
Start date: 2016-10-01
End date: 2019-09-30
Duration (months): 36.0
Total project cost (EUR): 3920302.5
EU funding (EUR): 3920302.5
Participants: 4
Project status: CLOSED

The COMPASS project is a collaborative effort of AVL, Plansee, Nissan and Research Center Jülich to develop advanced SOFC APU systems for range extender applications in passenger cars. The consortium is perfectly integrated from powder-, cell-, stack-, APU system technology providers to vehicle manufacturer and an academic partner. The project will use innovative metal supports SOFC stack technology, which enables key features like rapid start up and mechanic robustness for this application. Within the project advanced APU systems will be developed with electrical efficiency above 50%, a start up time below 15min and a small packaging size suitable for integration into battery electrical vehicles. Under the lead of NISSAN also a prototype vehicle will be build up, where an APU system will be completely integrated into the electrical powertrain. A major focus of the project is technology validation and systematic durability/reliability development. Therefore in a specific workpackage all validation activities are concentrated. The validation testing includes tests on stack, APU system and vehicle level. The APU system will furthermore undergo automotive testing like vibration, altitude, climate chamber and salt spray. In an additional dedicated workpackage manufacturing cost and business case analyses will be performed. These analyses will help to reduce the technology cost by design-to-cost and design-to-manufacture measures and show the business case of this new powertrain concept compared to other alternative and conventional propulsion concepts. This project is worldwide the first approach to integrate SOFC APU systems into electrical powertrains and will help to significantly improve APU systems also for other applications like heavy duty trucks, marine and leisure/camping.
Training Network for Optimizing Adoptive T cell Therapy of Cancer (T-OP)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Innovative Training Networks (ITN)-European Training Networks
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Germany,Germany,Israel,Germany,Switzerland,Switzerland,France,France,Netherlands,Denmark,Denmark,United Kingdom
Call: Innovative Training Networks (H2020-MSCA-ITN-2020, 2020)
Start date: 2021-03-01
End date: 2025-02-28
Duration (months): 48.0
Total project cost (EUR): 4100958.72
EU funding (EUR): 4100958.7199999997
Participants: 12
Project status: SIGNED

Over the last years, immunotherapy – using a patient’s own immune system to fight tumours – has emerged as an important complement to standard treatments. The clinical implementation of immunotherapeutics has established T cells as efficient anti-cancer weapons if targeted by specific drugs. Their therapeutic utilization has recently come to a breakthrough: adoptive T cell therapy (ACT), collecting and transforming the patient’s own T cells to treat cancer. An estimated 753 different cell therapies are currently in development, of which 375 are in clinical trials worldwide. The global cell therapy market was valued at $2.70 billion in 2018 and is expected to reach $8.21 billion in 2025. While European pharmaceutical companies and research institutions rank amongst the world leaders in basic and preclinical aspects of immunity including cell therapy development, clinical innovations and approvals in this field have largely been pioneered in other countries, especially in the USA and in China. The generation of such ACT products is a complex but ill-defined process with limited harmonization across production and clinical studies, even for the same indication. Cytokines are proteins responsible for the growth and differentiation of T cells. They are central to the generation procedure, whilst also playing a key role in the efficacy and safety of the cellular product. There is however a limited understanding as to which cytokines might lead to the best outcome on any of these steps. T-OP targets a pioneering research question: how do cytokines influence the therapeutic outcome of ACT products? T-OP brings together interdisciplinary and cross-sectorial teams spanning large and small-sized companies as well as experts in different aspects of cell therapy, immunology, protein engineering and bioinformatics. T-OP will train by research 15 ESR, enabling them to develop efficient therapeutic solutions and to tackle economic opportunities.

Keywords: t cell therapy,t cell engineering,cytokines,cytokine support,cytokine signalling
Providing services under Horizon 2020 enhancing the innovation management capacity of Hungarian SME's within the framework of the Enterprise Europe Network - 2015-16 (INNO-HUN2015-16)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: Specific Grant agreement
Countries involved: Hungary,Hungary,Hungary,Hungary,Hungary,Hungary,Hungary,Hungary
Call: Enhancing the innovation management capacity of SMEs (H2020-Adhoc-2014-20, 2014)
Start date: 2015-01-01
End date: 2016-12-31
Duration (months): 24.0
Total project cost (EUR): 150075.38
EU funding (EUR): 150075.37
Participants: 10
Project status: CLOSED

Establishing services enhancing the innovation management capacity of Hungarian SME's in the Enterprise Europe Network The global objective of the services delivered under this project is to effectively contribute to the innovation driven competitiveness and sustainable growth of the European economy via improving the innovation management processes in SMEs enabling them to get their products, services successfully on the market. The concept of this project focuses on the development of Innovation Management capabilities via two different types of high-added value services: • “Key account management” for the beneficiaries of the SME Instrument • “Enhancing SME innovation management capacity” provided independently from a specific project to innovating SMEs with a clear potential to go international

Keywords: enterprise europe network,horizon 2020,key account management,enhancing sme,innovation management capacity,sme instrument
Assembly Planning and SIMulation of an Aircraft Final Assembly Line (SIMFAL)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Theme: Public-private partnerships
Destination: Clean Sky 2
Action type: Innovation actions
Partnership: CS2 (Art-187)
Countries involved: Spain,Spain
Call: Assembly Planning and Simulation of an Aircraft Final Assembly Line (FAL) (H2020-CS2-CFP03-2016-01, 2016)
Start date: 2017-02-01
End date: 2020-01-31
Duration (months): 36.0
Total project cost (EUR): 563986.25
EU funding (EUR): 499719.13
Participants: 2
Project status: CLOSED

Many tasks in the assembly of an aircraft, such as the assembly of the interior components in the Cabin and Cargo areas, are performed manually, in non-ergonomic conditions, and with complex process chains. Recent advanced in robotics enable the completion of tasks between robots and human worker. Thus, the future of assembly of interior components in these areas will benefit with these new technologies. However, the planning of assembly tasks in which a human worker collaborates with a robot in a complex and many times narrow environment is extremely challenging. Many factor have to be analysed including the perception of different types of workers, logistic issues, addressing unexpected situation such as a malfunctioning of a robot, etc. New technologies such as Virtual Reality (VR) allows the study of this problem in a safe and cost effective way. Meanwhile Augmented Reality (AR) allows the inclusion of relevant information obtained from computational sources (such as the state of the robot, or new assembly plans) in their proper real context. The SIMFAL project proposes to develop a new testing tools based on VR to help aircraft manufacturers plan and evaluate different assembly alternatives. The information obtained in the VR simulator will be analysed to obtain the main factors that affect its performance. As a result, the advantages and disadvantages of different strategies of collaboration between the robot and the human will be obtained. This tool will also generate support data for an AR-based assistance tool based. The tool will provide information about the current assembly strategy, the current state of the system (including logistics, the robot, etc.) and maintenance information. This tool will also integrate a tool to help the worker to decide between alternative action plans under unexpected situations. A concept of middleware will be developed during the project to integrate the solution with the current design tools.

Keywords: virtual reality,augmented reality,human robot coexistence,automation,assembly,simulation,planning
VIROME NGS ANALYSIS OF PESTS AND PATHOGENS FOR PLANT PROTECTION (VIROPLANT)

Framework: Horizon 2020 — Societal Challenges
Programme: Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy
Theme: Sustainable agriculture and forestry
Action type: Research and Innovation actions
Countries involved: Italy,Spain,Spain,Italy,Germany,Germany,Italy,Italy,Belgium,Belgium,Finland,France,France,Netherlands,United Kingdom,United Kingdom,United Kingdom
Call: Innovations in plant protection (H2020-SFS-2017-2, 2017)
Start date: 2018-05-01
End date: 2021-10-31
Duration (months): 42.0
Total project cost (EUR): 3331580.0
EU funding (EUR): 3331580.0
Participants: 19
Project status: CLOSED

Next generation sequencing (NGS) technology has proved to be pivotal for elucidating the complexity and the role of the microbiome associated with plant and animals. The role of the “virome” as a sub-component of the microbiome is beginning to be unveiled because of new ways to analyse the data and in recognition of its importance in shaping biological systems. The aim of VIROPLANT is to apply NGS technology and empirical biological experiments to develop new environmentally friendly virus-based control strategies to manage bacterial, fungal and insect vector-transmitted diseases (phytoplasmas and viruses) as well as insect pests. So far, plant protection through viruses has relied on limited successful model systems, such as baculoviruses for lepidopterans, and one mycovirus for the control of chestnut blight; moreover, viruses infecting bacteria (phages) are also state of the art tools with potential to cope with antibiotic resistant bacterial strains in human and veterinary medicine. VIROPLANT will create a database of new viruses (and virus derived biotechnological products) to increase the arsenal for the control of plant diseases caused by the most important biotic stresses. Different NGS and bioinformatics approaches will be applied to explore the virome diversity, including latent infections that can be potentially exploited for new biocontrol strategies. Protocols of risk assessment will be implemented for virome-based model control strategies. VIROPLANT will address the social and gender-specific perception of the use of virome-based techniques as alternatives to traditional pesticides. A business plan for representative categories of virome-based control strategies will be included. Small and medium enterprises and stakeholders will be involved in bringing the most promising products to the market. The consortium will cover experts in insect virome, phage therapy and mycoviruses from different agro-ecological systems throughout Europe.

Keywords: virus,rnai,vigs